Adial Pharmaceuticals, Inc. (ADIL)

Several events have impacted Adial Pharmaceuticals' stock in the past six months. The company announced a warrant inducement transaction generating approximately $2.86 million in gross proceeds on November 26, 2025, and reported Third Quarter 2025 Financial Results and a business update on November 14, 2025. The CEO was featured on The Big Biz Show on October 17, and the company partnered with Genomind for precision medicine testing on October 9. Adial Pharmaceuticals provided a business update following favorable comments from its FDA End-of-Phase 2 (EOP2) Meeting for AD04 on September 16, 2025, after successfully completing the EOP2 meeting on August 6, 2025. The stock price has significantly declined over the past year, from $1.07 per share on January 2, 2025, to $0.22 per share on December 31, 2025, representing a 79.44% decrease. The 52-week high for the stock was $1.30 and the low was $0.22.

As a clinical-stage biopharmaceutical company, Adial Pharmaceuticals does not have established seasonality in product demand. However, stock performance analysis over the past six years suggests a seasonal tendency, with a "Buy Date" of November 28 and a "Sell Date" of March 1, showing a geometric average return of 33.2% above the S&P 500 Total Return Index. This analysis is based on limited data and may not be fully reliable.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, particularly Alcohol Use Disorder (AUD). Their main product, AD04, is in Phase 3 clinical trials and aims to reduce alcohol cravings and prevent relapse. The company is also developing drugs for non-opioid pain reduction and other diseases, and it owns a subsidiary called Purnovate, Inc.

Adial Pharmaceuticals, Inc. is headquartered in Glen Allen and Richmond, Virginia. The company's market presence is concentrated in North America and Europe, with the goal of establishing AD04 as a leading pharmaceutical intervention in these regions.

While specific brand reputation metrics are not directly available, recent events suggest positive developments in Adial Pharmaceuticals' scientific and regulatory standing. The successful completion of the FDA End-of-Phase 2 meeting for AD04 and the positive feedback received from the FDA regarding the Phase 3 clinical trial design are favorable for the company's reputation within the biopharmaceutical community. Additionally, the issuance of new patents strengthens its intellectual property portfolio. The significant decline in stock price over the past year could indirectly affect investor confidence.

Adial Pharmaceuticals, Inc. has a diverse ownership structure. Institutional investors hold 16.41% of the company's stock, insiders own 19.25%, and retail investors account for 78.21%. Major institutional owners include Geode Capital Management, Llc, Vanguard Group Inc, Citadel Advisors Llc, Manchester Capital Management LLC, FSMAX - Fidelity Extended Market Index Fund, BlackRock, Inc., UBS Group AG, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Two Sigma Securities, Llc, Jane Street Group, Llc, Armistice Capital LLC, and Intracoastal Capital, L.L.C. Key individual owners (insiders) include Cary J. Claiborne, William B. Stilley Iii, Bankole A. Johnson, James W. Newman Jr., Joseph Truluck, Robertson H. Gilliland, and Howard Peikin.